2025
SJR Q3
JCR Q2 · 2,9
126 matched articles
SCIE
Journal detail
Journal of Clinical Psychopharmacology
- Publisher
- Lippincott Williams and Wilkins
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
027107491533712X
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,523
- Quartile Q3
- H-Index 137
- Cites/doc 1,4
- Docs (3y) 427
- Cites (3y) 603
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,9
- 5Y JIF 2,8
- JCI 0,61
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Pharmacology (medical) Q3
- Psychiatry and Mental Health Q3
Areas
- Medicine
WoS categories
- Pharmacology & Pharmacy | Psychiatry
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q2 | 0,523 | 2,9 | 2,8 | 0,61 | Q3 | 137 |
| 2024 | Q2 | Q2 | 0,725 | 2,8 | 3 | 0,7 | Q2 | 135 |
| 2023 | Q2 | Q2 | 0,728 | 2,9 | 3 | 0,63 | Q3 | 135 |
| 2022 | Q2 | Q3 | 0,641 | 2,9 | 3 | 0,62 | Q3 | 135 |
| 2021 | Q2 | Q3 | 0,679 | 3,1 | 3,6 | 0,57 | Q3 | 135 |
| 2020 | Q2 | Q3 | 0,786 | 3,2 | 3,5 | 0,65 | Q3 | 135 |
| 2019 | Q2 | Q2 | 0,951 | 2,7 | 3 | 0,77 | Q2 | 135 |
| 2018 | — | Q2 | — | 3 | 3 | 0,84 | Q2 | — |
| 2017 | Q2 | Q2 | 1,054 | 3,1 | 3 | 0,83 | Q2 | 135 |
| 2016 | Q1 | Q2 | 1,122 | 2,9 | 3,4 | — | — | 135 |
| 2015 | Q1 | Q2 | 1,154 | 3 | 3,6 | — | — | 135 |
| 2014 | Q1 | Q2 | 1,174 | 3,2 | 3,6 | — | — | 135 |
| 2013 | Q1 | Q1 | 1,484 | 3,8 | 4,3 | — | — | 135 |
| 2012 | Q1 | Q1 | 1,41 | 3,5 | 4,5 | — | — | 135 |
| 2011 | Q1 | Q1 | 1,705 | 4,1 | 4,8 | — | — | 135 |
| 2010 | Q1 | Q1 | 1,763 | 4,9 | 4,7 | — | — | 135 |
| 2009 | — | Q1 | — | 5,1 | 4,7 | — | — | — |
| 2008 | — | Q1 | — | 4,4 | 4,6 | — | — | — |
| 2007 | — | Q1 | — | 3,9 | 4,5 | — | — | — |
| 2006 | — | Q1 | — | 4,6 | — | — | — | — |
| 2005 | — | Q1 | — | 5,1 | — | — | — | — |
| 2004 | — | Q1 | — | 4,4 | — | — | — | — |
| 2003 | — | Q1 | — | 4,4 | — | — | — | — |
| 2002 | — | Q1 | — | 4,2 | — | — | — | — |
| 2001 | — | Q1 | — | 4 | — | — | — | — |
| 2000 | — | Q1 | — | 5,1 | — | — | — | — |
| 1999 | — | Q1 | — | 5,7 | — | — | — | — |
| 1998 | — | Q1 | — | 5,3 | — | — | — | — |
| 1997 | — | Q1 | — | 5,1 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 173/356 |
| 2025 | PSYCHIATRY | SCIE | Q2 | Q3 | 119/293 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 157/352 |
| 2024 | PSYCHIATRY | SCIE | Q2 | Q3 | 106/288 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 147/354 |
| 2023 | PSYCHIATRY | SCIE | Q2 | Q3 | 98/279 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 163/278 |
| 2022 | PSYCHIATRY | SCIE | Q3 | Q3 | 99/155 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 170/279 |
| 2021 | PSYCHIATRY | SCIE | Q3 | Q3 | 101/155 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 154/276 |
| 2020 | PSYCHIATRY | SCIE | Q3 | Q3 | 88/156 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 134/271 |
| 2019 | PSYCHIATRY | SCIE | Q2 | Q2 | 69/155 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 106/267 |
| 2018 | PSYCHIATRY | SCIE | Q2 | Q2 | 60/146 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 85/261 |
| 2017 | PSYCHIATRY | SCIE | Q2 | Q2 | 50/142 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 99/257 |
| 2016 | PSYCHIATRY | SCIE | Q2 | — | 57/142 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 76/255 |
| 2015 | PSYCHIATRY | SCIE | Q2 | — | 47/142 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 69/255 |
| 2014 | PSYCHIATRY | SCIE | Q2 | — | 46/140 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 47/256 |
| 2013 | PSYCHIATRY | SCIE | Q1 | — | 32/136 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 57/261 |
| 2012 | PSYCHIATRY | SCIE | Q1 | — | 33/135 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 41/261 |
| 2011 | PSYCHIATRY | SCIE | Q1 | — | 25/130 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 21/252 |
| 2010 | PSYCHIATRY | SCIE | Q1 | — | 16/128 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 20/237 |
| 2009 | PSYCHIATRY | SCIE | Q1 | — | 12/117 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 29/219 |
| 2008 | PSYCHIATRY | SCIE | Q1 | — | 15/101 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 35/205 |
| 2007 | PSYCHIATRY | SCIE | Q1 | — | 20/94 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 24/199 |
| 2006 | PSYCHIATRY | SCIE | Q1 | — | 10/94 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 19/193 |
| 2005 | PSYCHIATRY | SCIE | Q1 | — | 6/94 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 20/187 |
| 2004 | PSYCHIATRY | SCIE | Q1 | — | 8/90 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 19/185 |
| 2003 | PSYCHIATRY | SCIE | Q1 | — | 7/87 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 18/188 |
| 2002 | PSYCHIATRY | SCIE | Q1 | — | 8/88 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 17/186 |
| 2001 | PSYCHIATRY | SCIE | Q1 | — | 10/81 |
| 2000 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 7/137 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 8/181 |
| 2000 | PSYCHIATRY | SCIE | Q1 | — | 5/82 |
| 1999 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 4/132 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 6/175 |
| 1999 | PSYCHIATRY | SCIE | Q1 | — | 5/80 |
| 1998 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 4/125 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 7/178 |
| 1998 | PSYCHIATRY | SCIE | Q1 | — | 3/77 |
| 1997 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 4/107 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 8/157 |
| 1997 | PSYCHIATRY | SCIE | Q1 | — | 3/67 |